Understanding Oral Mucositis

Oral mucositis is a severely
debilitating condition
characterized by erythema,
edema, and ulcerations of
the oral mucosa.

StatPearls Publishing; 2025 Jan

The WHO grading system for oral mucositis

Oral Mucositis leads to effects such as:

Opportunistic Infections

Fever

Oral Ulcerations

Anorexia, Haemorrhages

Pain, Dysphagia & Dysgeusia

Longer Period of Hospitalizations

Increasing the cost of therapy

Oral Mucositis in India

Info Cards Section

India has a high and rising cancer burden, making it a major public health issue.

A significant (40–100%) number of head and neck cancer patients receiving RT or CT develop mucositis.

Mucositis and its management play a prominent role in the success of cancer treatment.

Causes severe pain, difficulty in eating, reduced nutrition, weight loss, therapy delays, hospitalization, expenses, and life-threatening infections.

Affects motivation and compliance to therapy and may lead to discontinuation of chemotherapy or radiation therapy due to uncontrolled symptoms and pain.

1.Shah S, Rath H, Sharma G, Senapati SN, Mishra E. Effectiveness of curcumin mouthwash on radiation-induced oral mucositis among head and neck cancer patients: A triple-blind, pilot randomised controlled trial. Indian J Dent Res 2020;31:718-27. 2.Dharman S, G M, Shanmugasundaram K, Sampath RK. A Systematic Review and Meta-Analysis on the Efficacy of Curcumin/Turmeric for the Prevention and Amelioration of Radiotherapy/Radiochemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Asian Pac J Cancer Prev. 2021 Jun 1;22(6):1671-1684. 3.Saldanha SP, Almeida VD. A Comparative Study to Assess the Effectiveness of Turmeric Mouth Wash versus Saline Mouth Wash on Treatment Induced Oral Mucositis (Tiom) in a Selected Hospital at Mangalore. 2014 J Clinic Res Bioeth 5: 200. 4.Shankar A, Roy S, Bhandari M, Rath GK, Biswas AS, Kanodia R, Adhikari N, Sachan R. Current Trends in Management of Oral Mucositis in Cancer Treatment. Asian Pac J Cancer Prev. 2017 Aug 27;18(8):

Oral Mucositis

A Hidden Obstacle in Cancer treatment

Defend Mucosa, Deliver Comfort…

Let’s fight it out …

Dosage

CTRT (Adults)

One lozenge 4–6 times a day for 4–7 days from the first day of therapy until 1 week after the last CRT administration (for the management of oral mucositis), or as advised by the physician.

HSCT (Above 10 Years)

One lozenge 3–6 times a day for 4–7 days before initiation of chemotherapy and continued until resolution of mucositis or till day +24 post stem cell infusion, whichever occurs earlier (for prevention of oral mucositis), or as advised by the physician.

LEVISCD2 lozenges are intended to be dissolved slowly in the mouth.

Do not chew, crush or swallow the whole lozenge.

Do not consume anything 30 minutes before and after taking LEVISCD2

Mode of administration

Storage and handling:

To be stored between 2-8 °C
(in a refrigerator) protected
from light and moisture.

Do not freeze. Keep out of
reach of children